Type 4a myocardial infarction


Cite item

Full Text

Abstract

An increase in the level of cardiac troponins and creatine kinase MB is sometimes observed even after angiographically and clinically uncomplicated percutaneous coronary interventions. This review article deals with the clinical and prognostic implications of type 4a myocardial infarction.

Full Text

Инфаркт миокарда типа 4а. - Аннотация. Повышение уровня кардиоспецифичных тропонинов и фракции МВ креатинкиназы иногда отмечается даже после ангиографически и клинически неосложненных чрескожных коронарных вмешательств. Обзор посвящен клинической и прогностической значимости ИМ типа 4а.
×

About the authors

O Iu Mironova

References

  1. Thygesen K., Alpert J.S., White H.D. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-2538; Circulation 2007; 116: 2634-2653; J Am Coll Cardiol 2007; 50: 2173-2195.
  2. Thygesen K., Alpert J.S., White H.D. Third Universal Definition of Myocardial Infarction. JACC 2012; 60 (16): 1581-1598.
  3. Jeremias A., Baim D.S., Ho K.K. et al. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol 2004; 44: 1210 -1214.
  4. Brener S.J., Ellis S.G., Schneider J., Topol E.J. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002; 23: 869-876.
  5. Ellis S.G., Chew D., Chan A. et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002; 106: 1205-1210.
  6. Stone G.W., Mehran R., Dangas G. et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001; 104: 642-647.
  7. Ioannidis J.P., Karvouni E., Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003; 42: 1406-1411.
  8. Tardiff B.E., Califf R.M., Tcheng J.E. et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention: IMPACT-II Investigators Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999; 33: 88-96.
  9. Ghazzal Z., Ashfaq S., Morris D.C. et al. Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J 2003; 145: 1006-1012.
  10. Bertinchant J.P., Polge A., Ledermann B. et al. Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol 1999; 84: 51-57.
  11. Fuchs S., Kornowski R., Mehran R. et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000; 85: 1077-1082.
  12. Garbarz E., Iung B., Lefevre G. et al. Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol 1999; 84: 515-518.
  13. Gruberg L., Fuchs S., Waksman R. et al. Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcome analysis. Catheter Cardiovasc Interv 2002; 55: 174-179.
  14. Nallamothu B.K., Chetcuti S., Mukherjee D. et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol 2003; 91: 1272-1274.
  15. Ricciardi M.J., Davidson C.J., Gubernikoff G. et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003; 145: 522-528.
  16. Kini A.S., Lee P., Marmur J.D. et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93: 18-23.
  17. Natarajan M.K., Kreatsoulas C., Velianou J.L. et al. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 2004; 93: 750-753.
  18. Cavallini C., Savonitto S., Violini R. et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 26: 1494-1498.
  19. Nienhuis M.B., Ottervanger J.P., Bilo H.J. et al. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovascr Interv 2008; 71 (3): 318-324.
  20. Hermann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26: 2493-2519.
  21. Ricciardi M.J., Wu E., Davidson C.J. et al. Visualization of discrete microinfarction after percutaneous interventions associated with mild creatine kinase-MB elevation. Circulation 2001; 103: 2780-2783.
  22. Selvanayagam J.B., Porto I., Channon K. et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005; 111: 1027-1032.
  23. Saadeddin S.M., Habbab M.A., Sobki S.H., Ferns G.A. Association of systemic inflammatory state with troponin I elevation after elective uncomplicated percutaneous coronary intervention. Am J Cardiol 2002; 89: 981-983.
  24. Zairis M.N., Ambrose J.A., Ampartzidou O. et al. Preprocedural plasma C-reactive protein levels, postprocedural creatine kinase-MB release, and long-term prognosis after successful coronary stenting (four-year results from the GENERATION study). Am J Cardiol 2005; 95: 386-390.
  25. Gurm H.S., Bhatt D.L., Gupta R. et al. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Heart J 2003; 146: 692-698.
  26. Kojima S., Sakamoto T., Ishihara M. et al. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann Med 2004; 36: 153-160.
  27. Bonderman D., Teml A., Jakowitsch J. et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99: 2794-2800.
  28. Mizuno O., Hojo Y., Ikeda U. et al. Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol 2000; 85: 154-160.
  29. Ray M.J., Walters D.L., Bett J.N. et al. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab. Int J Cardiol 2005; 101: 249-255.
  30. Leosco D., Fineschi M., Pierli C. et al. Intracoronary serotonin release after high-pressure coronary stenting. Am J Cardiol 1999; 84: 1317-1322.
  31. Petronio A.S., Amoroso G., Limbruno U. et al. Endothelin-1release from atherosclerotic plaque after percutaneous transluminal coronary angioplasty in stable angina pectoris and single-vessel coronary artery disease. Am J Cardiol 1999; 84: 1085-1088.
  32. Herrmann J. Periprocedural myocardial injury: 2005 update. Eur Heart J 2005; 26: 2493-2519.
  33. Janse M.J., Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989; 69: 1049-169.
  34. Zimarino M., Corazzini A., Tatasciore A. et al. Defective recovery of QT dispersion predicts late cardiac mortality after percutaneous coronary intervention. Heart 2011; 97: 466-472.
  35. Lansky A.J., Stone G.W. Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention. Circulation 2010; 3: 602-610.
  36. Argulian E., Patel A., Abramson J.L. et al. Gender Differences in Short-Term Cardiovascular Outcomes After Percutaneous Coronary Interventions. Am J Cardiol 2006; 98: 48-53.
  37. Lansky A., Hochman J., Ward P. et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women. A statement for Healthcare Professionals from the American Heart Association. Circulation 2005; 111: 940-953.
  38. Prasad A., Gersh B.J., Bertrand M.E. et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54: 477-486.
  39. Chaitman B.R., Hardison R.M., Adler D. et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120: 2529-2540.
  40. Moussa I.D., Klein L.W., Shah B. et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI). Cathet Cardiovasc Intervent 2014; 83: 27-36.
  41. Novack V., Pencina M., Cohen D.J. et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med 2012; 172: 502-508.
  42. Lim C.C., van Gaal W.J., Testa L. et al. With the "universal definition", measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol 2011; 57: 653-661.
  43. Brener S.J., Lytle B.W., Schneider J.P. et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002; 40: 1961-1967.
  44. Akkerhuis K.M., Alexander J.H., Tardiff B.E. et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002; 105: 554-556.
  45. Abdelmeguid A.E., Ellis S.G., Sapp S.K. et al. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996; 131: 1097-1105.
  46. Akkerhuis K.M., Alexander J.H., Tardiff B.E. et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002; 105: 554-556.
  47. Dangas G., Mehran R., Feldman D. et al. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. Am J Cardiol 2002; 89: 586-589.
  48. Hong M.K., Mehran R., Dangas G. et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999; 100: 2400-2405.
  49. Kong T.Q., Davidson C.J, Meyers S.N. et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997; 277: 461-466.
  50. Saucedo J.F., Mehran R., Dangas G. et al. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000; 35: 1134-1141.
  51. Topol E.J., Ferguson J.J., Weisman H.F. et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 479-484.
  52. Акинина С.А. Сравнительное прогностическое значение креатинфосфокиназы МВ-фракции и тропонина Т при диагностике перипроцедурного повреждения миокарда. Рос кардиол журн 2012; 3: 19-24.
  53. Silber S., Albertsson P., Aviles F.F. et al.; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
  54. Smith S.C., Feldman T.E., Hirshfeld J.W. Jr et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writting Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2006; 113: 156-175.
  55. Serruys P.W., De Feyter P.J., Benghozi R. et al. The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebocontrolled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 2001; 4: 165-172.
  56. Herrmann J., Lerman A., Baumgart D. et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-2183.
  57. Chan A.W., Bhatt D.L., Chew D.P. et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-696.
  58. Chan A.W., Bhatt D.L., Chew D.P. et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107: 1750-1756.
  59. Dangas G., Smith D.A., Unger A.H. et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83: 688-692.
  60. Topol E.J., Mark D.B., Lincoff A.M. et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomized trial: EPISTENT Investigators Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019-2024.
  61. Kastrati A., Mehilli J., Neumann F.J. et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies